{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis&page=20",
    "query": {
      "condition": "Myelofibrosis",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 476,
    "total_pages": 48,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelofibrosis&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T04:39:25.091Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00079222",
      "title": "Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "itraconazole",
          "type": "DRUG"
        },
        {
          "name": "voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079222"
    },
    {
      "nct_id": "NCT04640532",
      "title": "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Post-PV MF",
        "Post-ET Myelofibrosis",
        "Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "KRT-232",
          "type": "DRUG"
        },
        {
          "name": "TL-895",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2020-11-17",
      "completion_date": "2025-07-24",
      "has_results": false,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Whittier, California • Lake City, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Fort Lee",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640532"
    },
    {
      "nct_id": "NCT01369498",
      "title": "Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Simtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2011-06-30",
      "completion_date": "2014-09-24",
      "has_results": true,
      "last_update_posted_date": "2020-07-01",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Stanford, California • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369498"
    },
    {
      "nct_id": "NCT04637009",
      "title": "A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myeloproliferative Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "TAS1553",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astex Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-12-21",
      "completion_date": "2023-02-20",
      "has_results": false,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04637009"
    },
    {
      "nct_id": "NCT00890747",
      "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",
        "Acute Undifferentiated Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Adult Langerhans Cell Histiocytosis",
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Aggressive NK-cell Leukemia",
        "AIDS-related Diffuse Large Cell Lymphoma",
        "AIDS-related Diffuse Mixed Cell Lymphoma",
        "AIDS-related Diffuse Small Cleaved Cell Lymphoma",
        "AIDS-related Immunoblastic Large Cell Lymphoma",
        "AIDS-related Lymphoblastic Lymphoma",
        "AIDS-related Malignancies",
        "AIDS-related Small Noncleaved Cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Chronic Eosinophilic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Clear Cell Renal Cell Carcinoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "de Novo Myelodysplastic Syndromes",
        "Essential Thrombocythemia",
        "Extramedullary Plasmacytoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "HIV Infection",
        "HIV-associated Hodgkin Lymphoma",
        "Intraocular Lymphoma",
        "Isolated Plasmacytoma of Bone",
        "Light Chain Deposition Disease",
        "Mast Cell Leukemia",
        "Myelodysplastic Syndrome With Isolated Del(5q)",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloid/NK-cell Acute Leukemia",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Osteolytic Lesions of Multiple Myeloma",
        "Peripheral T-cell Lymphoma",
        "Plasma Cell Neoplasm",
        "Polycythemia Vera",
        "Post-transplant Lymphoproliferative Disorder",
        "Previously Treated Myelodysplastic Syndromes",
        "Primary Myelofibrosis",
        "Primary Systemic Amyloidosis",
        "Progressive Hairy Cell Leukemia, Initial Treatment",
        "Prolymphocytic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Renal Cell Cancer",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Stage IV Renal Cell Cancer",
        "T-cell Large Granular Lymphocyte Leukemia",
        "Testicular Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2009-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-03-17",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00890747"
    },
    {
      "nct_id": "NCT00053157",
      "title": "Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 10,
      "start_date": "2002-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053157"
    },
    {
      "nct_id": "NCT00114257",
      "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114257"
    },
    {
      "nct_id": "NCT02784496",
      "title": "Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Long-term Follow-up",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2016-09-29",
      "completion_date": "2024-01-23",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784496"
    },
    {
      "nct_id": "NCT00005805",
      "title": "St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Fatigue",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "St. John's wort",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005805"
    },
    {
      "nct_id": "NCT06063486",
      "title": "Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clonal Cytopenia of Undetermined Significance",
        "Essential Thrombocythemia",
        "Myelodysplastic Syndrome",
        "Myelofibrosis",
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Piperine Extract (Standardized)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-03-01",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-22T04:39:25.091Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06063486"
    }
  ]
}